HOME >> BIOLOGY >> NEWS
Anti-interferon beta antibodies in MS care: A consensus

t for MS," urged Frederick Munschauer, M.D. "As new information becomes available, this should be factored into the patient's care. For now, selection of MS therapy should be based on how effective the treatment is over the long-term in light of the potential impact NAbs can have among these therapies. Currently, if a patient develops NAbs, physicians are forced to consider a more toxic or less effective agent."

What is multiple sclerosis?

Multiple sclerosis (MS) is an autoimmune disease that affects the central nervous system (CNS). The CNS consists of the brain, spinal cord, and the optic nerves. Surrounding and protecting the nerve fibers of the CNS is a fatty tissue called myelin, which helps nerve fibers conduct electrical impulses. Myelin not only protects nerve fibers but also makes their job possible.

In MS, myelin is destroyed in multiple areas, leaving scar tissue. These damaged areas are also known as plaques or lesions, and sometimes the nerve fiber itself is damaged or broken. When myelin or the nerve fiber is destroyed or damaged, the ability of the nerves to conduct electrical impulses to and from the brain is impaired or disrupted, and this produces the various symptoms of MS, such as vision problems, numbness, loss of balance, difficulty walking and paralysis.


'"/>

Contact: Cindy Gessell
cindy.gessell@ketchum.com
201-652-4778
Ketchum
14-Feb-2004


Page: 1 2 3

Related biology news :

1. Researchers find clues about how antibodies specialize
2. Second generation targeted antibodies - Its all in the binding
3. Researchers show autoantibodies occur before lupus in New England Journal of Medicine
4. Programmable antibodies-- hybrid cancer therapy described by scientists at Scripps
5. Bodys own antibodies may drive new strains of HIV
6. Growing human antibodies in algae
7. Blasting antibodies with lasers provides direct way of measuring their flexibilities
8. Ozone produced by antibodies during bacterial killing and in inflammation
9. Artificial antibodies created by new molecular imprinting process
10. Human antibodies against spores found by researchers suggest new tool to detect and treat anthrax
11. Scientists at The Scripps Research Institute discover a previously unknown role for antibodies

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Anti interferon beta antibodies care consensus

(Date:5/18/2015)... -- Fingerprint Cards (FPC) has received an order ... FPC1035 from one if its module partners. Deliveries are planned ... and the sensors will be used by smartphone manufacturers in ... hereby amount to 740 MSEK to date. In addition to ... a number of smaller orders not separately communicated amounting to ...
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/7/2015)... GOTHENBURG, Sweden , May 7, 2015 /PRNewswire/ ... new touch fingerprint sensors, FPC1022 and FPC1035, FPC,s ... FPC1022 and FPC1035 are mainly considered for integration ... decreased size gives smartphone OEMs increased possibilities to ... portfolio. The decreased size also improves possibilities for ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
(Date:5/21/2015)...  The EveryLife Foundation for Rare Diseases applauded ... Amy Klobuchar (D-MN) today for introducing the ... or OPEN ACT. Supported by more ... bipartisan legislation promises to rapidly bring hundreds of ... patients by incentivizing drug makers to "repurpose" approved ...
(Date:5/21/2015)... 21, 2015 W. R. Grace ... facility in Worms, Germany has received good manufacturing ... of the International Pharmaceutical Excipient Council (IPEC) Foundation. ... produce its SYLOID® FP brand of pharmaceutical grade ... following the Curtis Bay, Maryland (USA) and Sorocaba, ...
(Date:5/21/2015)... ANGELES , May 21, 2015  CytRx ... and development company specializing in oncology, today announced ... clinical trial with aldoxorubicin for the treatment of ... brain cancer.  The open-label, multisite trial is designed ... aldoxorubicin in patients whose tumors have progressed following ...
(Date:5/21/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/84975r/2015_global ) ... Global Survey on Flow Cytometry Adoption Trends" ... goal of this research is to analyze the ... information the survey seeks to collect include factors ... used applications for flow cytometers, respondents, most preferred ...
Breaking Biology Technology:Advocates Cheer Senate Leaders for Introducing Bipartisan Bill to Increase Number of Rare Disease Treatments 2Grace European Facility Receives GMP Excipient Certification for SYLOID® FP Silica Gel 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Global Survey on Flow Cytometry Adoption Trends 2015 2
Cached News: